Miglustat (Miglustat) Patent Expiration, LOE Window & CMS Spending

Miglustat (Miglustat) by Ani Pharmaceuti: Multi-Source Generic Molecule, 3 AB generics, $14.9M 2024 CMS Part D & Medicaid spend, and $14,362 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAni Pharmaceuti
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$14.9M
2024 Medicare Part D Spend$4.6M
2024 Medicaid Spend$10.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($14,362 intro WAC)